Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Hongmei Jing, Doctor
CONTACT
Lead
Peking University Third Hospital
With
This study is an early, open, single-centered trial. The major aim of this study is to evaluate the safety and tolerance of GC019F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 6-12 subjects to receive GC019F single infusion.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted